Amanote Research
Register
Sign In
Persistence Rate With Subcutaneous Biologic Therapies in Patients With Rheumatoid Arthritis (Ra)
Value in Health
- United Kingdom
doi 10.1016/j.jval.2014.08.2634
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
November 1, 2014
Authors
R. Lyu
Q. Ding
M. Govoni
T. Fan
Publisher
Elsevier BV
Related search
Persistence Rate With Subcutaneous Biologic Therapies in Patients With Ankylosing Spondylitis (As)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Biologic Monotherapy in the Biologic Naïve Patient With Rheumatoid Arthritis (RA): Results From an Observational Study
Rheumatology International
Rheumatology
Allergy
Immunology
Persistence With Biologic Agents for the Treatment of Rheumatoid Arthritis in Japan
Patient Preference and Adherence
Pharmacology
Health Policy
Medicine
Toxicology
Social Sciences
Pharmaceutics
SAT0200 Biologic Therapy Retention in Rheumatoid Arthritis (RA) Patients (PTS) According to the Moscow Arthritis Registry (MAR)
Unmet Needs and Biologic Use Among Patients With Rheumatoid Arthritis in Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Treatment Persistence With Combination Versus Monotherapy in Commercially Insured Patients With Rheumatoid Arthritis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Risk of Hypersensitivity Associated With Biologic Use Among Medicare Patients With Rheumatoid Arthritis
Arthritis Care and Research
Rheumatology
Effect of Cryofiltration to Severe Rheumatoid Arthritis(RA) Patients With Secondary Amyloidosis.
Journal of the Japan Society of Blood Transfusion
Influenza Vaccination of Patients With Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)
Clinical and Developmental Immunology
